unexpected

Gome Fin Tech Announced Annual Results of 2023

Source Node:
Time Stamp: April 1, 2024 1:23 PM - Modified On: April 1, 2024 - Published By:
Source Cluster:
Republished By Plato

  Commercial Factoring Progresses Despite Stability Diversified Businesses Ready for Development HONG KONG, Mar 29, 2024 - (ACN Newswire) - Gome Finance Technology Co., Ltd.(Stock Code:628.HK,“Gome Fin Tech”or “the Company”,with its subsidiaries,the“Group”), announced its audited annual results for the year ended 31 December, 2023 (the “Reporting Period”). In 2023, the global geopolitical risks are frequent, the lack of economic recovery momentum and the widening trend of differentiation among countries are highlighted, and the risk spillover from European and US banks under the global high interest rate environment also casts a

Short Trading: A comprehensive analysis of the controversial strategy and an in-depth analysis of how investors make money from market declines

Source Node:
Time Stamp: March 19, 2024 8:45 AM - Modified On: March 19, 2024 - Published By:
Source Cluster:
Republished By Plato

Short trading is a strategy in which investors make money by taking advantage of predictions that a stock or other asset is expected to fall. The process involves borrowing shares and selling them immediately in the hope of buying them back at a lower price once their price drops, profiting from the difference between the selling and buying prices. Simply put, short trading is a way for investors to make profits through expected negative changes in the market. The Historical Origins of Short Trading The idea of ​​short trading can

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:16 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement